Antibody-drug conjugate specialist Tubulis GmbH has raised a hefty €308 million (US$356 million) series C to expand clinical development of TUB-040, positioning its lead program for use in additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback